发明名称 WT1 ANTIGEN PEPTIDE CONJUGATE VACCINE
摘要 A compound represented by the formula (1):;;wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2):;;wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.
申请公布号 US2015238587(A1) 申请公布日期 2015.08.27
申请号 US201514706772 申请日期 2015.05.07
申请人 Sumitomo Dainippon Pharma Co., Ltd. ;International Institute of Cancer Immunology, Inc. 发明人 LI Chiang Jia;Ban Hitoshi;Nishio Yukihiro;Goto Masashi;Nishihara Toshio;Takanashi Yosuke
分类号 A61K39/00;A61K47/48 主分类号 A61K39/00
代理机构 代理人
主权项 1. A method of treating cancer, comprising: administering a therapeutically effective amount of a pharmaceutical composition to a WT1 positive cancer patient in need thereof, the pharmaceutical composition comprising a compound represented by formula (1):  or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier,wherein Xa and Ya are each a single bond,cancer antigen peptide A is a peptide consisting of an amino acid sequence selected from the group consisting of:RMFPNAPYL,(SEQ ID NO: 2)ALLPAVPSL,(SEQ ID NO: 5)SLGEQQYSV(SEQ ID NO: 6)andRVPGVAPTL,(SEQ ID NO: 7)an amino group of an N-terminal amino acid of the cancer antigen peptide A binds to Ya in the formula (1), a carbonyl group of a C-terminal amino acid of the cancer antigen peptide A binds to a hydroxyl group in the formula (1),R1 is a cancer antigen peptide C,the cancer antigen peptide C has a sequence different from a sequence of the cancer antigen peptide A, which is a peptide consisting of an amino acid sequence selected from the group consisting of:CMTWNQMNL(SEQ ID NO: 3)andCYTWNQMNL,(SEQ ID NO: 4)and a thioether group of the cysteine residue of the cancer antigen peptide C is bonded to the thioether group in the formula (1).
地址 Osaka-shi JP